|Bid||4,460.00 x 51000|
|Ask||4,649.00 x 53800|
|Day's Range||4,517.00 - 4,640.50|
|52 Week Range||2,707.19 - 5,377.00|
|PE Ratio (TTM)||142.34|
|Dividend & Yield||0.26 (0.48%)|
|1y Target Est||N/A|
Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding in adults diagnosed with von Willebrand Disease.
Shire, Bellicum Pharmaceuticals and Organovo Holdings were among the biotech stock movers in premarket trading on June 22.
Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older